secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001013762-25-003432
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada reports FY2024 net loss $80M; cash $44.8M; new Phase 2 programs NDV-01 and sepranolone
--------------------------------------------------------------------------------

- Q4 2024 net loss $18.6M ($0.62/sh) vs $25.1M ($0.84/sh) in Q4 2023; FY2024 net loss $80M ($2.65/sh) vs $98.8M ($3.28/sh).
- Cash and short-term investments $44.9M at Dec 31, 2024, down from $96.3M at Dec 31, 2023; runway into H1 2026 based on plans.
- Topline Phase 2 data for NDV-01 (bladder cancer) expected at AUA April 26-29, 2025; Phase 2b-ready sepranolone for Tourette syndrome.
- Re-evaluating further development of REL-P11 due to competitive landscape in metabolic disease.
- R&D expense FY2024 $46.2M, down from $54.8M; G&A $37.7M vs $48.9M, reflecting cost-saving measures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000101376225003432/0001013762-25-003432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000101376225003432/ea0236006-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001013762-25-003432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer